businesspress24.com - Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum
 

Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum

ID: 1269520

(firmenpresse) - LONDON, ONTARIO -- (Marketwired) -- 10/03/13 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company"), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will be presenting at the 12th Annual BIO Investor Forum () on Wednesday, October 9, 2013, at 9:30 a.m. PDT in San Francisco.

Dr. Danter will highlight the Company's innovative drug discovery platform technology and two-pronged commercial validation and revenue strategy during the live presentation. Dr. Danter will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.

An online investor kit, including the Company's investor presentation and fact sheet, are available on the Company's corporate blog at .

Follow (at)CriticalOutcome and the official conference feed on Twitter, and join the conversation by using #BIF13.

About Critical Outcome Technologies Inc. (COTI)

COTI is a leading-edge technology company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit .

Follow (at)CriticalOutcome on Twitter at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Critical Outcome Technologies Inc.




Dr. Wayne Danter
President & CEO
519-858-5157



Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Boston Therapeutics Closes $5.3 Million in Private Placement of Common Stock and Warrants
Theratechnologies to Announce Third Quarter 2013 Financial Results
Bereitgestellt von Benutzer: Marketwired
Datum: 03.10.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 1269520
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

LONDON, ONTARIO


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 67 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Critical Outcome Technologies to Present at the 12th Annual BIO Investor Forum
"
steht unter der journalistisch-redaktionellen Verantwortung von

Critical Outcome Technologies Inc. (COTI) (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Critical Outcome Technologies Inc. (COTI)



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 106


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.